[Clinical implications of bisphosphonate for bone metastases of prostate cancer].
Kitagawa
Yasuhide
Y
Department of Urology, School of Medicine, Kanazawa University.
Konaka
Hiroyuki
H
Mizokami
Atsushi
A
Namiki
Mikio
M
D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000209:etiology / Q000517:prevention & control / Q000556:secondary*; D001862:Bone Resorption / Q000517:prevention & control; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D010010:Osteoclasts / Q000502:physiology; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology*; D053245:RANK Ligand / Q000502:physiology; D016032:Randomized Controlled Trials as Topic
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D053245:RANK Ligand